



PATENT
Attorney Docket 061525-5011

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Miekka et al.**

Application No. 09/960,703

Filing Date: September 24, 2001

For: Methods for sterilizing biological materials containing non-aqueous solvents

Art Unit: 1744

Examiner: **Krisanne Jastrzab**

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97(c)

Pursuant to 37 C.F.R. 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449. This Information Disclosure Statement is being filed to the best of the undersigned's knowledge before the mailing date of a Final Office Action or a Notice of Allowance for the above-referenced application. Under the provisions of 37 C.F.R. 1.97(c), the Commissioner is hereby authorized to charge the fee of \$180.00 as specified by 1.17(p) to Deposit Account 50-0310. Documents aa to ac listed in this Information Disclosure Statement were cited by the Examiner in an Office Action in related U.S. Application 10/060,208.

Copies of the listed documents are attached. Applicants respectfully request that the Examiner consider the listed document and evidence their consideration by making appropriate notations on the attached form. This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the above-listed documents are material or constitute prior art. If the Examiner applies any document as prior art against any claim in the application and Applicants determine that the cited document does not constitute prior art under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such document.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention should the document be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. 1.16 and 1.17 which may be required, including any required extension of time fees, or

credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a **constructive petition for extension of time** in accordance with 37 C.F.R. 1.136(a)(3).

Dated: **January 26, 2005**
Morgan, Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
202-739-3000

Respectfully submitted
Morgan, Lewis & Bockius LLP



Robert Smyth
Registration No. 50,801



INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

PTO Form 1449

Attorney Docket **061525-5011-US**

Application No. **09/960,703**

Applicant: **Miekka *et al.***

Page **1** of **1**

Filing Date: **September 24, 2001**

Group: **1744**

U.S. Patent Documents

Examiner Initial	Document No.	Date	Name	Class	Sub Class	Filing Date

Foreign Patent Documents

	Document No.	Date	Country	Class	Sub Class	<u>Translation</u>
aa	WO 88/06043	Aug. 25, 1988	PCT			
ab	DE 38 17 603	Nov. 30, 1989	Germany			No
ac	DD 280466	July 11, 1990	Germany			No

Other Documents

Examiner:	Date Considered
-----------	-----------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication.